Valhalla Vitality Review: A Peptide Store That Will Not Tell You What Is In the Vial Until You Are a Patient

GLP-1 (T) and GLP-1 (S)

The clearest consequence is on the weight-loss line, and it is worth stating precisely because it is unusual enough to sound like an error.

Valhalla's injectable weight-loss products are called GLP-1 (T) and GLP-1 (S). Those are the names on the product cards, in the variant labels, in the categories, in the copy. The service page adds only: "What is GLP-1 vs GLP-1+? Your clinician may consider GLP-1 or GLP-1+ options based on your needs; choices are made case-by-case after your eligibility check."

Across all 113 non-blog pages — 20,845,917 characters, downloaded on August 9, 2026 — the lower-case strings "semaglutide" and "tirzepatide" appear zero times. Capitalised, they appear seven times each, and every occurrence is inside the JSON payload as a product tag: "Tirzepatide", "Semaglutide", "Sublingual Tirzepatide", "Sublingual Semaglutide". Never in a sentence. Never on a card. Never anywhere a reader is looking.

The molecules themselves have as much evidence behind them as anything in medicine. STEP 1 randomised 1,961 adults to once-weekly semaglutide or placebo. ^{1 2} SURMOUNT-1 randomised 2,539 to tirzepatide or placebo. ^{3 4} Those are the trials that changed the field.

None of that reaches the reader, because the reader is not told which molecule is in the syringe. And the distinction matters for more than curiosity: the two drugs have different mechanisms, different effect sizes, different side-effect profiles and different dosing. A patient who cannot name their own medication cannot look up any of it, cannot check an interaction, and cannot tell an emergency physician what they are on. If you want the difference in plain terms, it is a dual agonist against a single one, and it is not a detail.

The gonadorelin problem

Behind the gate is a product almost nobody reviews, and it turns out to be the most interesting thing on the site.

Valhalla sells Gonadorelin Therapy, injectable and as an oral rapid-dissolve tablet. Its description: "Gonadorelin is a synthetic form of gonadotropin-releasing hormone, also known as GnRH… In provider-guided wellness protocols, Gonadorelin may be used when supporting healthy hormone communication is part of the patient's personalized treatment plan. It is often discussed in connection with reproductive wellness, natural testosterone-related signaling, and pituitary-gonadal axis support."

The first sentence is textbook-accurate. Gonadorelin is GnRH, and GnRH does prompt the pituitary to release luteinising hormone and follicle-stimulating hormone.

Now check the label. DailyMed lists five current gonadorelin drug labels in the United States. ⁸ All five are animal drugs. Factrel — the brand under which gonadorelin was used in human endocrinology — is now marketed by Zoetis, and its label reads "For use in cattle only", carries the caution "Federal law restricts this drug to use by or on the order of a licensed veterinarian", and gives the indication as "the treatment of ovarian follicular cysts in lactating dairy cows, beef cows, and replacement dairy and beef heifers." ⁹ Cystorelin, Fertagyl, Gonabreed and Ovacyst are the same story under different names.

This does not mean Valhalla is dispensing a veterinary product — a compounding pharmacy works from active ingredient, not from a Zoetis bottle, and nothing found in this review suggests otherwise. It means something subtler and more useful: there is no marketed FDA-approved human gonadorelin product in the United States, so there is no human label to check a claim against. No indication, no dosing, no contraindications, no adverse-reaction table written for a person.

The registry does not fill the gap. A ClinicalTrials.gov search for gonadorelin narrowed to hypogonadism returns 33 studies; narrowed to male hypogonadism with testosterone in the query, 12. Read them and they are diagnostic provocative testing of the pituitary-gonadal axis, pulsatile GnRH for idiopathic hypogonadotropic hypogonadism, and pituitary stalk interruption syndrome — congenital and post-surgical failures of the axis. Not one studies gonadorelin as ongoing "support" for an axis that works.

"Pituitary-gonadal axis support" is not a claim the literature can confirm or deny, because it is not an outcome anybody has measured.

PT-141: right for half its audience

The sexual-health line is where Valhalla's evidence is strongest and its wording is loosest, in the same paragraph.

The service page: "PT-141 therapy offers a science-backed path to enhanced libido and a more fulfilling intimate life." And: "PT-141 may be an option for men seeking support for libido and erectile function, as well as women seeking support for low sexual desire." $200 a month — the only price on the public site.

For women, "science-backed" is fair. Bremelanotide has two completed phase 3 trials, RECONNECT 301 and 302, enrolling 723 and 714 premenopausal women with hypoactive sexual desire disorder, published in Obstetrics & Gynecology in 2019. ^{5 6} It holds an FDA approval on the strength of them. Most sellers of compounded PT-141 aim it squarely at men and ignore the population it was actually studied in; Valhalla does not, and that is worth saying.

For men, the approved label answers the page directly. Under Limitations of Use: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance." ⁷ A ClinicalTrials.gov search for bremelanotide as an intervention returns ten studies; restricted to erectile dysfunction as a condition, zero.

So one clause of that sentence rests on 1,437 randomised participants and one rests on nothing, and the reader is given no way to tell which is which.

The combination troches make it harder again. Valhalla sells PT-141 blended with oxytocin and tadalafil, described as "[c]ombines arousal support with ingredients commonly used for connection and performance." Each of the three has its own literature; the blend has none. The registered evidence for oxytocin and sexual function is a single completed phase 2 trial in 30 women. ¹³ Three evidence bases do not add up when you mix them — they produce a fourth product nobody has tested.

Sermorelin, NAD+, and one sentence about testing

Two more products, briefly, because the pattern is by now familiar and the details still matter.

Sermorelin Therapy is sold "to support the body's natural growth hormone signaling" for "recovery, vitality, body composition, and overall wellness". The mechanism clause is true. As of August 2026 a PubMed search for sermorelin filtered to randomised controlled trials returns 19 records, and the newest was published in 2005. ¹⁰ Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures recovery, body composition or vitality in a healthy adult. Two of Valhalla's three formulations blend sermorelin with theanine or NAD+, which adds ingredients without adding trials. This is the general shape of the problem across the whole growth-hormone-secretagogue family, and it is worth reading once properly.

NAD+ Therapy carries the strongest evidence language on the site: "Scientifically proven: Research-backed and rigorously tested for purity, safety, and potency." As of August 2026, a PubMed search for NAD+ with an injected route, filtered to randomised controlled trials, returns four records, and only one actually gives NAD+ by an injected route — a 2026 placebo-controlled trial in heart failure caused by ischaemic cardiomyopathy. ^{11 12} Not longevity, not DNA repair, not healthy adults.

Notice what that single bullet does. It runs "scientifically proven" and "rigorously tested for purity, safety, and potency" together as though they were one idea. They are two entirely different questions — does the molecule work, and does the vial contain what the label says — and neither answers the other. Certificates of analysis exist precisely to keep them apart.

Which brings up the last measurement. The phrase "rigorously tested" occurs once across all 113 non-blog pages. That one occurrence is the NAD+ marketing bullet. Across the same 20,845,917 characters, "USP" occurs zero times, "sterility" zero times, "certificate of analysis" zero times, "COA" zero times. The word "sterile" appears five times, all of them instructions about injection technique on the Trimix page.

So Valhalla asserts testing for one product line, in five words, and documents it for none.

What the gate actually costs

Set the evidence aside for a moment and look at the structure, because the structure is the thing that makes this review different from the others on this site.

A prospective patient at Valhalla Vitality cannot, before handing over an eligibility questionnaire, learn: which molecule they would be prescribed for weight loss; what any product costs, with one exception; which pharmacy would compound it; which states the service reaches; or what testing, if any, that pharmacy performs. Four of those five are published nowhere at all. The fifth — price — is published to their browser and withheld from their eyes.

The terms complete the picture. "You are physically located in a state where our healthcare providers are licensed to practice at the time of the telehealth consultation," followed by "[p]atients must verify their eligibility for telehealth services in their state prior to scheduling an appointment." The reader is asked to affirm a fact the company knows and does not publish, then to go and check it themselves.

Valhalla is not hiding a scandal behind that gate. What is behind it is an ordinary compounded-peptide catalogue with one genuinely well-evidenced product, several with mechanisms and no outcomes, and one whose only current American labels are written for cattle. The gate does not protect anyone from hard advertising. It protects the catalogue from being read.